Three merits of bringing TPT1 onboard in the battle against cervical cancer are in sight—opening an earlier window for cervical cancer intervention, circumvention of the obstacle of tissue sampling, and a prompt establishment of a tractable therapy option using current anti-TPT1 drugs. This evidence concerns the gene TPT1 and cervical carcinoma.